Dual ACE and NEP inhibitor therapy has shown enhanced efficacy in animal models of heart failure and cardiomyopathy, leading to the development of orally active molecules that inhibit both ACE and NEP, known as dual inhibitors [45,46]. The gene discussed is ACE; the disease is cardiomyopathy.